Le Lézard
Classified in: Health
Subject: ACC

SciBase publishes the Annual report for 2021


STOCKHOLM, April 22, 2022 /PRNewswire/ -- SciBase hereby announces that the Annual report for 2021 is available at the Company's website www.scibase.com.

A pdf-version of the annual report is enclosed to this press-release.

A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy.

For more information, please contact:

Michael Colérus, CFO
Tel: +46 70 341 34 72
E-mail: michael.colerus@scibase.com

Certified Advisor:

Vator Securities
Tel: +46 580 065 99
Email: ca@vatorsec.se 

The information was submitted for publication, through the agency of the contact person set out above, at 09.00 CET on April 22, 2022.

About SciBase and Nevisense

SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/scibase-publishes-the-annual-report-for-2021,c3550212

The following files are available for download:

https://mb.cision.com/Main/12371/3550212/1566960.pdf

Annual-report-2021-Final

https://mb.cision.com/Public/12371/3550212/a84743b8e7725e13.pdf

PR Annual Report 2021


These press releases may also interest you

16 aoû 2022
The peripheral guidewires market will be driven by factors such as the increasing demand for MI procedures. Peripheral guidewires are MI medical supplies that are used to access the peripheral vessels inside the human body. MI methods are replacing...

16 aoû 2022
The "Pulmonary Edema Therapeutics Market by Type (Cardiogenic pulmonary edema and Non-cardiogenic pulmonary edema) and Geography (North America, Europe, Asia, and Rest of World (ROW)) - Forecast and Analysis 2022-2026" report has been added to...

16 aoû 2022
A plethysmograph is a non-invasive, low-cost device that is used to measure the volume changes in different parts of the body, resulting from fluctuations in the amount of blood or air. The device uses blood pressure cuffs and sensors. It is used for...

16 aoû 2022
EverVet Partners ("EverVet" or the "Company"), one of the fastest growing veterinary services platforms in the U.S., today announced its partnership with Freeman Spogli & Co. ("Freeman Spogli"), a leading private equity investor in the consumer and...

16 aoû 2022
WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), announced today that it has once again been selected as a constituent of the FTSE4Good Index Series, and is the only...

16 aoû 2022
Endo International plc ("Endo" or the "Company") today announced...



News published on 22 april 2022 at 03:11 and distributed by: